Monday, October 28, 2024

CATEGORY

ICER

ICER Evaluates Cost-Effectiveness of ATTR-CM Treatments

Key TakeawaysICER’s report confirms that tafamidis, acoramidis, and vutrisiran provide significant health benefits for transthyretin amyloid cardiomyopathy (ATTR-CM). ICER suggests pricing tafamidis and...

New Screening Method for Early Preeclampsia Shows Promising Results in Catalonia

The rapid response report by the Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) suggests a major leap forward in preeclampsia screening. By...

Medicare Set to Include COPD Drugs in Next Round of Price Negotiations, ICER Prepares Evaluation

Key TakeawaysThe next round is expected to target COPD drugs like GSK's Breo Ellipta and Trelegy Ellipta. ICER is preparing a special report...

ICER to Assess New Treatment for Retinitis Pigmentosa

Key TakeawaysICER to assess the value and effectiveness of sonpiretigene isteparvovec for retinitis pigmentosa. Public comments on the Draft Scoping Document are open...

ICER Draft Report Evaluates Treatment for EBV+ PTLD

Key TakeawaysICER released a draft evidence report assessing the effectiveness and value of tabelecleucel for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease. Public...

August 2024 Milestones for Institute for Clinical and Economic Review

The Institute for Clinical and Economic Review (ICER) released important findings related to treatments in the field of anemia for myelodysplastic syndrome (MDS). These...

ICER Publishes Evidence Report on Transthyretin Amyloid Cardiomyopathy Treatments

Key Takeaways:ICER evaluates tafamidis, acoramidis, and vutrisiran for treating transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis and acoramidis offer health benefits at a cost-effective price...

ICER Report Highlights Pricing Concerns for Imetelstat in Myelodysplastic Syndrome Treatment

Key Takeaways:ICER's final evidence report indicates that the current pricing of imetelstat does not align with its modest clinical benefits in treating anemia...

July 2024 Milestones for Institute for Clinical and Economic Review

This month, the Institute for Clinical and Economic Review (ICER) has released several important reports and updates. These publications highlight ICER's dedication to assessing...

Assessing the Value of Suzetrigine for Acute Pain

The Institute for Clinical and Economic Review (ICER) has announced its plan to evaluate the comparative clinical effectiveness and value of suzetrigine (Vertex Pharmaceuticals)...

Transthyretin Amyloid Cardiomyopathy: ICER Assesses Effectiveness and Value of Treatments in Draft Report

The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of three treatments...

Chronic Obstructive Pulmonary Disease: ICER Evaluates Ensifentrine’s Effectiveness and Value

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of ensifentrine (Ohtuvayre,...

ICER Publishes Evidence Report on Anemia Treatment in Myelodysplastic Syndrome

The Institute for Clinical and Economic Review (ICER) has published a revised Evidence Report assessing the comparative clinical effectiveness and value of imetelstat (Rytelo,...

Post-Traumatic Stress Disorder Treatment Lacks Sufficient Evidence for MDMA-Assisted Psychotherapy

The Institute for Clinical and Economic Review (ICER) has published a Final Evidence Report assessing the comparative clinical effectiveness and value of MDMA-assisted psychotherapy...

June 2024 Milestones for Institute for Clinical and Economic Review

In June, the Institute for Clinical and Economic Review (ICER) released a series of significant evaluations and analyses aimed at assessing the effectiveness and...

Latest news